DGX 외환 뉴스
Haystack Oncology And Lisata Therapeutics Partner To Evaluate Efficacy Of Pancreatic Cancer Therapy
Haystack Oncology, a Quest Diagnostics (DGX) company, and Lisata Therapeutics, Inc. (LSTA), a clinical-stage pharmaceutical company, announced Thursday a research collaboration to use the Haystack MRD Technology to evaluate efficacy of Pancreatic Cancer Therapy.
RTTNews
|
103 일 전
Quest Diagnostics To Acquire Outreach Laboratory Services Of OhioHealth
Quest Diagnostics (DGX), a provider of diagnostic information services, and OhioHealth, a nationally recognized not-for-profit, charitable, integrated health system, announced Wednesday a definitive agreement for Quest to acquire select assets of OhioHealth's outreach laboratory services business.
RTTNews
|
111 일 전
Quest Diagnostics To Acquire LifeLabs From OMERS In About $985 Mln Deal
Quest Diagnostics (DGX), a provider of diagnostic information services, announced Wednesday a definitive agreement to acquire LifeLabs, a provider of community laboratory tests for millions of Canadians, from OMERS for a value of approximately C$1.35 billion (approximately $985 million), including net debt.
RTTNews
|
118 일 전
Quest Diagnostics Awarded Contract To Assess Burden Of Hepatitis C Virus In U.S By CDC
Quest Diagnostics (DGX), a leading provider of hepatitis testing services, announced Thursday it has been awarded a contract by the U.S. Centers for Disease Control and Prevention (CDC) designed to assess the burden of hepatitis C virus (HCV) in the U.S.
RTTNews
|
327 일 전
Quest, Scipher Team Up To Expand Diagnostic Services Access For Patients With Rheumatoid Arthritis
Diagnostic services provider Quest Diagnostics (DGX) and precision immunology company Scipher Medicine announced Tuesday a multi-pronged collaboration designed to expand patient access to diagnostic services advancing precision medicine for rheumatoid arthritis (RA).
RTTNews
|
336 일 전
Quest Diagnostics Narrows FY23 Adj. EPS Outlook Range, Boosts Revenue Forecast - Update
While reporting financial results for the third quarter on Wednesday, Quest Diagnostics Inc. (DGX) narrowed its earnings and adjusted earnings guidance range for the full-year 2023, while raising annual revenue outlook.
RTTNews
|
371 일 전
Quest Diagnostics Says FDA Grants Breakthrough Designation For Adeno-associated Virus Test
Quest Diagnostics (DGX), a diagnostic information services provider, announced Wednesday that its AAVrh74 ELISA assay (CDx) has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
RTTNews
|
426 일 전
Quest Diagnostics Boosts FY23 Adj. EPS, Revenue Outlook - Update
While reporting financial results for the second quarter on Wednesday, Quest Diagnostics Inc. (DGX) raised its adjusted earnings and revenue guidance for the full-year 2023.
RTTNews
|
461 일 전
Quest Diagnostics Guides FY23 Adj. EPS In Line With Estimates - Update
While reporting financial results for the fourth quarter on Thursday, Quest Diagnostics Inc. (DGX) initiated its earnings, adjusted earnings and revenue guidance for the full-year 2023.
RTTNews
|
635 일 전
Agilent Inks Deal With Quest Diagnostics To Offer CtDx FIRST Liquid Biopsy Test Across US
Agilent Technologies, Inc. (A) announced Monday an agreement with Quest Diagnostics (DGX), a diagnostic information services company, to enable providers and patients throughout the U.S. to access the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test.
RTTNews
|
645 일 전
